CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease.

@article{Rogacev2011CD14CD16MA,
  title={CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease.},
  author={Kyrill S. Rogacev and Sarah H Seiler and Adam M. Zawada and Birgit Reichart and E. M. U. C. K Herath and Daniel Roth and Christof Ulrich and Danilo Fliser and Gunnar Henrik Heine},
  journal={European heart journal},
  year={2011},
  volume={32 1},
  pages={84-92}
}
AIMS Patients with chronic kidney disease (CKD) pose a worldwide growing burden to health care systems due to accelerated atherosclerosis and subsequent high cardiovascular (CV) morbidity. Atherogenesis is prominently driven by monocytes and monocyte-derived macrophages. The expression of CD14 and CD16 characterizes three monocyte subsets: CD14(++)CD16(-), CD14(++)CD16(+), and CD14((+))CD16(+) cells; the latter two are often denoted as 'proinflammatory' CD16(+) monocytes. Despite an association… CONTINUE READING

From This Paper

Topics from this paper.
93 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 93 extracted citations

Similar Papers

Loading similar papers…